Cystic fibrosis antibiotic dosing: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{| class="wikitable sortable" |
{| class="wikitable sortable" |
||
! Medication |
! Medication |
||
| + | !Coverage |
||
! Dose |
! Dose |
||
| − | ! Frequency |
||
| − | ! Home IV |
||
|- |
|- |
||
| [[Aztreonam]] |
| [[Aztreonam]] |
||
| + | |[[Burkholderia cepacia]], [[Pseudomonas aeruginosa]] |
||
| − | | 2 g |
||
| − | | q8h |
+ | | 2 g IV q8h |
| − | | no |
||
|- |
|- |
||
| [[Cefazolin]] |
| [[Cefazolin]] |
||
| + | |[[Staphylococcus aureus]] |
||
| − | | 2 g |
||
| − | | q8h |
+ | | 2 g IV q8h |
| − | | yes |
||
|- |
|- |
||
| [[Cefipime]] |
| [[Cefipime]] |
||
| + | |[[Burkholderia cepacia]], [[Pseudomonas aeruginosa]] |
||
| − | | 2 g |
||
| − | | q8h |
+ | | 2 g IV q8h |
| − | | yes |
||
|- |
|- |
||
| [[Ceftazidime]] |
| [[Ceftazidime]] |
||
| + | |[[Achromobacter]], [[Burkholderia cepacia]], [[Pseudomonas aeruginosa]] |
||
| − | | 2 g |
||
| + | | 2-3 g IV q6-8h (max 12 g/day) |
||
| − | | q8h |
||
| + | |- |
||
| − | | yes |
||
| + | |[[Ceftazidime-avibactam]] |
||
| + | |[[Pseudomonas aeruginosa]] |
||
| + | |2.5 g IV q8h |
||
|- |
|- |
||
| [[Chloramphenicol]] |
| [[Chloramphenicol]] |
||
| + | |[[Achromobacter]], [[Burkholderia cepacia]] |
||
| − | | 500 mg to 1 g |
||
| + | | 12.5-25 mg/kg/dose IV q6h (max 1g/dose) with drug monitoring to target peak 10-20 mcg/mL and trough 5-10 mcg/mL |
||
| − | | q6h |
||
| − | | at SMH |
||
|- |
|- |
||
| [[Ciprofloxacin]] |
| [[Ciprofloxacin]] |
||
| + | |[[Achromobacter]], [[Pseudomonas aeruginosa]] |
||
| − | | 400 mg |
||
| + | | 400 mg IV q8h or 750 mg p.o. BID to TID |
||
| − | | q8h |
||
| − | | yes |
||
|- |
|- |
||
| [[Cloxacillin]] |
| [[Cloxacillin]] |
||
| + | |[[Staphylococcus aureus]] |
||
| − | | 2 g |
||
| − | | q6h |
+ | | 1-2 g IV q6h |
| − | | yes |
||
|- |
|- |
||
| [[Colistin]] |
| [[Colistin]] |
||
| + | |[[Achromobacter]], [[Pseudomonas aeruginosa]] |
||
| − | | 75 mg |
||
| + | | 2.5-5 mg/kg/day divided q8-12h (max 5 mg/kg/day) |
||
| − | | q8-12h |
||
| − | | yes |
||
|- |
|- |
||
| [[Meropenem]] |
| [[Meropenem]] |
||
| + | |[[Achromobacter]], [[Burkholderia cepacia]], [[Pseudomonas aeruginosa]] |
||
| − | | 2 g |
||
| − | | q8h |
+ | | 2 g IV q8h |
| − | | CADD pump |
||
|- |
|- |
||
| [[Piperacillin/tazobactam]] |
| [[Piperacillin/tazobactam]] |
||
| + | |[[Achromobacter]], [[Pseudomonas aeruginosa]] |
||
| − | | 4.5 g |
+ | | 4.5 g IV q4-6h |
| − | | q6-8h |
||
| − | | yes |
||
|- |
|- |
||
| [[Tigecycline]] |
| [[Tigecycline]] |
||
| + | |[[Achromobacter]], [[MRSA]], [[NTM]], [[Stenotrophomonas maltophilia]] |
||
| − | | 100 mg load, then 50 mg |
+ | | 100 mg IV load, then 50 mg IV q12h |
| − | | q12h |
||
| − | | no |
||
|- |
|- |
||
| [[Tobramycin]] |
| [[Tobramycin]] |
||
| + | |[[Pseudomonas aeruginosa]] |
||
| − | | 10 mg/kg |
||
| + | | 10 mg/kg/dose IV q24h with drug monitoring to target peak 20-40 mg/L and trough <1 mg/L |
||
| − | | q24h |
||
| − | | yes |
||
|- |
|- |
||
| [[Vancomycin]] |
| [[Vancomycin]] |
||
| + | |[[MRSA]] |
||
| − | | 1 g |
||
| + | | 15-20 mg/kg/dose IV q8-12h to target trough 15-20 mg/L; or 15-20 mg/kg IV load then 30-40 mg/kg/day (max 60 mg/kg/day) IV continuous infusion, target steady state level 20-25 mg/L |
||
| − | | q8h |
||
| − | | yes |
||
|} |
|} |
||
| + | Source: [https://www.cysticfibrosis.ca/uploads/Antibiotic%20Dosing%20Guideline%20Aug%202021.pdf CF Canada] |
||
| − | '''Source:''' St. Michael's Hospital |
||
[[Category:Infectious diseases]] |
[[Category:Infectious diseases]] |
||
Latest revision as of 11:29, 20 June 2023
| Medication | Coverage | Dose |
|---|---|---|
| Aztreonam | Burkholderia cepacia, Pseudomonas aeruginosa | 2 g IV q8h |
| Cefazolin | Staphylococcus aureus | 2 g IV q8h |
| Cefipime | Burkholderia cepacia, Pseudomonas aeruginosa | 2 g IV q8h |
| Ceftazidime | Achromobacter, Burkholderia cepacia, Pseudomonas aeruginosa | 2-3 g IV q6-8h (max 12 g/day) |
| Ceftazidime-avibactam | Pseudomonas aeruginosa | 2.5 g IV q8h |
| Chloramphenicol | Achromobacter, Burkholderia cepacia | 12.5-25 mg/kg/dose IV q6h (max 1g/dose) with drug monitoring to target peak 10-20 mcg/mL and trough 5-10 mcg/mL |
| Ciprofloxacin | Achromobacter, Pseudomonas aeruginosa | 400 mg IV q8h or 750 mg p.o. BID to TID |
| Cloxacillin | Staphylococcus aureus | 1-2 g IV q6h |
| Colistin | Achromobacter, Pseudomonas aeruginosa | 2.5-5 mg/kg/day divided q8-12h (max 5 mg/kg/day) |
| Meropenem | Achromobacter, Burkholderia cepacia, Pseudomonas aeruginosa | 2 g IV q8h |
| Piperacillin/tazobactam | Achromobacter, Pseudomonas aeruginosa | 4.5 g IV q4-6h |
| Tigecycline | Achromobacter, MRSA, NTM, Stenotrophomonas maltophilia | 100 mg IV load, then 50 mg IV q12h |
| Tobramycin | Pseudomonas aeruginosa | 10 mg/kg/dose IV q24h with drug monitoring to target peak 20-40 mg/L and trough <1 mg/L |
| Vancomycin | MRSA | 15-20 mg/kg/dose IV q8-12h to target trough 15-20 mg/L; or 15-20 mg/kg IV load then 30-40 mg/kg/day (max 60 mg/kg/day) IV continuous infusion, target steady state level 20-25 mg/L |
Source: CF Canada
